<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03405363</url>
  </required_header>
  <id_info>
    <org_study_id>1222.54</org_study_id>
    <nct_id>NCT03405363</nct_id>
  </id_info>
  <brief_title>Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists</brief_title>
  <official_title>Cohort Study of Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease Initiating Olodaterol or Other Long-acting beta2-agonists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or
      all-cause mortality in COPD patients who are new users of Olodateror or other LABAs available
      for the treatment of COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose:

      Time Perspective:
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">March 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of atrial fibrillation or flutter</measure>
    <time_frame>1 year</time_frame>
    <description>during new use of Olodaterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalisation for ventricular tachycardia, ventricular fibrillation/flutter and cardiac arrest</measure>
    <time_frame>1 year</time_frame>
    <description>during new use of Olodaterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of supraventricular tachycardia</measure>
    <time_frame>1 year</time_frame>
    <description>(other than atrial fibrillation/flutter) during new use of Olodaterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalisation for acute myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>during new use of Olodaterol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of hospitalisation for serious acute coronary heart disease, including unstable angina</measure>
    <time_frame>1 year</time_frame>
    <description>during new use of Olodaterol</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>new users of Olodaterol</arm_group_label>
    <description>COPD patients using Olodaterol for the first time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>new users of other LABAs</arm_group_label>
    <description>COPD patients using other long-acting beta2 agonists for the first time</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        COPD patients
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  COPD diagnosis

          -  aged 40 years or older (to minimise the likelihood of including individuals who have
             asthma only)

          -  New user of olodaterol or a new user of indacaterol, salmeterol, or formoterol (not in
             fixed-dose combination with an inhaled corticosteroid) and have no dispensing of any
             LABA in the 6 months before the index date

          -  at least 1 year of enrolment in the electronic database before their first LABA
             dispensing (defined as the index LABA)

          -  Complete data on sex

        Exclusion criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus Universitets hospital Skejby</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>May 15, 2018</last_update_submitted>
  <last_update_submitted_qc>May 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

